Schirm USA, a subsidiary of Schirm in Germany, has appointed Chad Kern (48) as chief executive officer (CEO), effective Aug. 1, 2019. He succeeds Gus Jones, who will retire in September.
Kern holds a BS in agriculture from Southern Illinois University and has worked in the chemical industry for 20 years. He joined Schirm more than 11 years ago and held various positions in purchasing, EH&S, as lead engineer and facility construction manager. In his most recent role he served as director of manufacturing.
In a separate news, Schönebeck, Germany-headquartered Schirm announced the appointment of Trevor Roberts (43) as chief operating officer (COO), effective Jul. 3, 2019.
In his position, Roberts will support the management team of Dirk Unterstenhöfer (CEO) and Alfred Ludorf (CFO) in the operating business and also take over the complete responsibility for all four Schirm business locations in Germany.
Before joining Schirm, Roberts held various management positions at Schirm’s parent company, the South African AECI Group, most recently as chief procurement officer.
most read
Ineos Invests £30 Million to Slash Emissions at Hull Site by 75%
Ineos has completed a major £30 million investment at its Hull manufacturing site, converting the facility to run on clean-burning hydrogen instead of natural gas. This results in a 75% cut in carbon emissions.
Novo Nordisk Invests $1.09 Billion in Brazil
Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.
BASF Divests Two Joint Ventures in China
BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.
Roche and Zealand Pharma Collaborate on Weight Management Drug
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
Arkema Launches Acrylic Acid Purification Project
Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.